表紙
市場調查報告書

注射式藥物輸送設備市場:成長率,趨勢,及預測(2019年 - 2024年)

Injectable Drug Delivery Devices Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 871451
出版日期 內容資訊 英文 114 Pages
商品交期: 2-3個工作天內
價格
Back to Top
注射式藥物輸送設備市場:成長率,趨勢,及預測(2019年 - 2024年) Injectable Drug Delivery Devices Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年05月01日內容資訊: 英文 114 Pages
簡介

本報告提供注射式藥物輸送設備市場的相關調查,市場概況和成長要素、阻礙因素,各設備類型、治療用途、地區的市場分析,競爭情形,主要企業的簡介等資訊彙整。

目錄

第1章 簡介

  • 研究成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 慢性疾病的罹患率增加
    • 導致自行注射的需求增加的優點與便利性
    • 導致注射器的需求增加的生技藥品市場成長
  • 市場阻礙因素
    • 針造成的受傷和感染
    • 替代投藥法的使用擴大
  • 波特五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各設備類型
    • 傳統的藥物輸送設備
    • 自我給藥型藥物輸送設備
  • 各治療用途
    • 循環系統疾病
    • 糖尿病
    • 腫瘤學
    • 自體免疫疾病
    • B型肝炎
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東及非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Alkermes
    • Baxter International, Inc.
    • Becton, Dickinson and Company
    • Eli Lilly and Company
    • Gerresheimer AG
    • Novartis AG
    • Pfizer, Inc.
    • Schott AG
    • Terumo Corporation
    • Teva Pharmaceutical Industries Ltd

第7章 市場機會及今後趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 52626

Market Overview

The injectable drug delivery devices market will show rapid growth due to the increasing prevalence of chronic diseases, benefits and convenience leading to increased demand of self injectors and growth of biologics market leading to increased demand for injectors.

The increasing prevalence of chronic diseases has led to a rise in the overall use of syringes, particularly disposable syringes. It has been observed that most deaths by chronic diseases can be attributed to cardiovascular diseases, obesity, and diabetes. This is expected to affect the emerging countries the most, as population growth is found to be the most significant factor in developing areas.

A major number of drugs and therapies that address these chronic ailments are now found to be available. However, the use of syringes in the management of any chronic ailment is inevitable. Syringes can either be a part of sample collection during diagnosis or treatment regimen, like osteoarthritis. Consequently, the rise in the prevalence of chronic diseases is expected the drive the growth of the market studied.

Furthermore, technological advancements, improving patient compliance, beneficial reimbursement policies, and the rise of biologics in the pharmaceutical market are some of the other factors propelling the growth of the market.

Scope of the Report

As per the scope of the report, the injectable devices are being used to administer drugs either intravenously, through intramuscular or subcutaneously and are considered as injectable drug delivery devices. The injectable method is the frequently used method for drugs that have poor oral bioavailability, targeted drug delivery system, and delivery of drugs at the site of action. Injectable drug delivery is used in conditions such as hormonal imbalance, cystic fibrosis, autoimmune diseases, pain, Wilson's disease, hemophilia, hepatitis C, and ribose-5-phosphate isomerase deficiency.

Key Market Trends

Self-injectable Drug Delivery Devices is Anticipated to be the Dominant During the Forecast Period

There have been boundless innovations and developments in self-injectable devices driving the growth of the market. The other major advantages associated with self-injectable injections are found to be convenient usage and low healthcare cost. These self-injectables were developed by taking account of patient feedback, to provide the most adaptable device which has a high precision of drug delivery and is easy to use.

In addition, with the innovations in self-injectable devices, the acceptance of these products has increased over the past few years. Nevertheless, the advantages of self-injectable injections and increasing awareness of self-administration have helped in driving the overall market studied during the forecast period.

North America Region Dominates the Market of Injectable Drug Delivery Devices Market

North America has been found dominating the injectable drug delivery devices due to the increasing aging population and the rising number of chronic diseases that may influence the usage of injectables. According to the National Cancer Institute, 2018, there were an estimated 1,735,350 new cases of cancer that were being diagnosed in the United States. Therefore the chemotherapy drugs are being delivered to these cancer patients through injectable devices. Hence, increasing prevalence of chronic diseases and the adoption of new technologies related to injectables in the United States may help in propelling the growth of the overall market.

There are also some of the other factors that include; the large pool of patient population, increasing healthcare expenditure, rising focus of various companies, increasing healthcare awareness, an increase in government funding. Hence all these factors are found associated with the growth of the market.

Competitive Landscape

The companies present in the market are found focusing on product innovations, expansions, finding new markets or innovating their core competency to expand their individual market share. There are also innovations taking place in injectable drug delivery systems that are the trend for the global injectable drug delivery market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Chronic Diseases
    • 4.2.2 Benefits and Convenience leading to Increased demand of Self Injectors
    • 4.2.3 Growth of Biologics Market leading to Increased demand for injectors
  • 4.3 Market Restraints
    • 4.3.1 Injuries & Infections Caused by Needles
    • 4.3.2 Growing Use of Alternative Delivery Methods
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Devices Type
    • 5.1.1 Conventional Drug Delivery Devices
    • 5.1.2 Self-Injectable Drug Delivery Devices
      • 5.1.2.1 Prefilled Syringes
      • 5.1.2.2 Injectable Pens
      • 5.1.2.3 Auto-Injectors
      • 5.1.2.4 Needle-free Injectors
      • 5.1.2.5 Others
  • 5.2 By Therapeutic Application
    • 5.2.1 Cardiovascular Disease
    • 5.2.2 Diabetes
    • 5.2.3 Oncology
    • 5.2.4 Autoimmune Disorders
    • 5.2.5 Hepatitis B
    • 5.2.6 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Alkermes
    • 6.1.2 Baxter International, Inc.
    • 6.1.3 Becton, Dickinson and Company
    • 6.1.4 Eli Lilly and Company
    • 6.1.5 Gerresheimer AG
    • 6.1.6 Novartis AG
    • 6.1.7 Pfizer, Inc.
    • 6.1.8 Schott AG
    • 6.1.9 Terumo Corporation
    • 6.1.10 Teva Pharmaceutical Industries Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top